HomeBIOCON • NSE
Biocon Ltd
₹379.25
Jan 15, 2:16:29 PM GMT+5:30 · INR · NSE · Disclaimer
StockIN listed securityIN headquartered
Previous close
₹387.65
Day range
₹378.65 - ₹391.50
Year range
₹244.55 - ₹395.80
Market cap
454.33B INR
Avg Volume
4.40M
P/E ratio
31.54
Dividend yield
0.13%
Primary exchange
NSE
CDP Climate Change Score
B
In the news
Financials
Income Statement
Revenue
Net income
(INR)Sep 2024Y/Y change
Revenue
35.90B3.70%
Operating expense
21.42B8.03%
Net income
-160.00M-112.74%
Net profit margin
-0.45-112.40%
Earnings per share
-0.19-115.53%
EBITDA
6.78B-6.58%
Effective tax rate
72.46%
Total assets
Total liabilities
(INR)Sep 2024Y/Y change
Cash and short-term investments
26.50B-30.00%
Total assets
571.28B4.67%
Total liabilities
304.08B0.36%
Total equity
267.20B
Shares outstanding
1.23B
Price to book
2.27
Return on assets
Return on capital
1.56%
Net change in cash
(INR)Sep 2024Y/Y change
Net income
-160.00M-112.74%
Cash from operations
Cash from investing
Cash from financing
Net change in cash
Free cash flow
About
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA. Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Founded
1978
Website
Employees
16,315
Search
Clear search
Close search
Google apps
Main menu